Aarti Pharmalabs Limited is a prominent manufacturer of APIs, pharmaceutical intermediates, NCEs, and Xanthine derivatives. The company specializes in developing HPAPIs for therapeutic segments like anticancer and anti-asthma medications.

In recent years, Aarti Pharmalabs has expanded its manufacturing capabilities, notably with projects such as the Atali Greenfield site and enhanced Xanthine production. These projects highlight the company’s focus on capacity expansion to meet growing demand and increase market share.

The company maintains a strong R&D focus with multiple state-of-the-art centers, contributing to both product innovation and strategic partnerships, particularly within the CDMO sector.

Despite showing growth in several segments, the company's profitability faced challenges due to margin pressures and forex losses, impacting overall financial performance this year.

Aarti Pharmalabs is strategically poised in global markets with certifications from USFDA, EU GMP, and more, illustrating a commitment to maintaining high regulatory standards and expanding its international footprint.